Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190033 | 0.79 | TDP1 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL14213484 | 0.79 | CYP2A6 (0.33) | ALDH1A1CYP2A6LMNA | |
| SCHEMBL29569254 | 0.76 | HTT (0.41) | KDM4EALDH1A1LMNA | |
| SCHEMBL22161609 | 0.76 | CYP2A6 (0.31) | CYP2A6 | |
| SCHEMBL1709918 | 0.76 | HTT (0.41) | KDM4EALDH1A1LMNA | |
| SCHEMBL14213485 | 0.76 | HSD17B10 (0.50) | ALDH1A1MAPT | |
| SCHEMBL7601802 | 0.76 | ALDH1A1 (0.37) | KDM4EALDH1A1CYP2A6LMNAMAPT | |
| SCHEMBL20589216 | 0.76 | MAPT (0.31) | MAPT | |
| SCHEMBL3713429 | 0.76 | XDH (0.37) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL7602435 | 0.76 | EGFR (0.36) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635949-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4471034-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLE METHYL KETONE DERIVATIVE AND APPLICATION THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024125395-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-06-20 | — | — | WO | disclosed |
| EP-3083560-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3083560-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3083560-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095444-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095444-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | KDM4E 3815/4885ALDH1A1 489/4885CYP2A6 865/4885 |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, TYRO3 | KDM4E 1078/4885ALDH1A1 3044/4885CYP2A6 2665/4885 |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | KDM4E 379/4885ALDH1A1 1671/4885CYP2A6 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.